Role of moesin in HMGB1-stimulated severe inflammatory responses

Summary

Sepsis is a life-threatening condition that arises when the body’s response to infection causes systemic inflammation. High-mobility group box 1 (HMGB1), as a late mediator of sepsis, enhances hyper-permeability, and it is therefore a therapeutic target. Despite extensive research into the underlying mechanisms of sepsis, the target molecules controlling vascular leakage remain largely unknown. Moesin is a cytoskeletal protein involved in cytoskeletal changes and para-cellular gap formation. The objectives of this study were to determine the roles of moesin in HMGB1-mediated vascular hyperpermeability and inflammatory responses and to investigate the mechanisms of action underlying these responses. Using siRNA knockdown of moesin expression in primary human umbilical vein endothelial cells (HUVECs), moesin was found to be required in HMGB1-induced F-actin rearrangement, hyperpermeability, and inflammatory responses. The mechanisms involved in moesin phosphorylation were analysed by blocking the binding of the HMGB1 receptor (RAGE) and inhibiting the Rho and MAPK pathways. HMGB1-treated HUVECs exhibited an increase in Thr558 phosphorylation of moesin. Circulating levels of moesin were measured in patients admitted to the intensive care unit with sepsis, severe sepsis, and septic shock; these patients showed significantly higher levels of moesin than healthy controls, which was strongly correlated with disease severity. High blood moesin levels were also observed in cecal ligation and puncture (CLP)-induced sepsis in mice. Administration of blocking moesin antibodies attenuated CLP-induced septic death. Collectively, our findings demonstrate that the HMGB1-RAGE-moesin axis can elicit severe inflammatory responses, suggesting it to be a potential target for the development of diagnostics and therapeutics for sepsis.

Keywords

Moesin - HMGB1 - vascular permeability - sepsis - marker

^* First two authors contributed equally to this work.

• References

• 1 Wang H, Bloom O, Zhang M. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
• 2 Bae JS. Role of high mobility group box 1 in inflammatory disease: Focus on sepsis. Arch Pharm Res 2012; 35: 1511-1523.
• 3 Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003; 09: 517-524.
• 4 Mackenzie I, Lever A. Management of sepsis. Br Med J 2007; 335: 929-932.
• 5 Yang H, Ochani M, Li J. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101: 296-301.
• 6 Gautreau A, Louvard D, Arpin M. ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organisation and cell growth signalling. Curr Opin Cell Biol 2002; 14: 104-109.
• 7 Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 03: 586-599.
• 8 Gautreau A, Louvard D, Arpin M. Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J Cell Biol 2000; 150: 193-203.
• 9 Amar S, Oyaisu K, Li L. et al. Moesin: a potential LPS receptor on human monocytes. J Endotoxin Res 2001; 07: 281-286.
• 10 Iontcheva I, Amar S, Zawawi KH. et al. Role for moesin in lipopolysaccharide-stimulated signal transduction. Infect Immun 2004; 72: 2312-2320.
• 11 Koss M, Pfeiffer 2nd GR, Wang Y. et al. Ezrin/radixin/moesin proteins are phosphorylated by TNF-alpha and modulate permeability increases in human pulmonary microvascular endothelial cells. J Immunol 2006; 176: 1218-1227.
• 12 Bae JS, Lee W, Nam JO. et al. Transforming Growth Factor beta-induced Protein Promotes Severe Vascular Inflammatory Responses. Am J Respir Crit Care Med 2014; 189: 779-786.
• 13 Ku SK, Han MS, Lee MY. et al. Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo. BMB Rep 2014; 47: 336-341.
• 14 Ku SK, Bae JS. Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and FIIa/FXa. Arch Pharm Res 2014; 37: 1454-1463.
• 15 Hofbauer R, Moser D, Salfinger H. et al. Sufentanil inhibits migration of human leukocytes through human endothelial cell monolayers. Anesth Analg 1998; 87: 1181-1185.
• 16 Bae JS, Rezaie AR. Thrombin inhibits HMGB1-mediated proinflammatory signalling responses when endothelial protein C receptor is occupied by its natural ligand. BMB Rep 2013; 46: 544-549.
• 17 Bone RC, Balk RA, Cerra FB. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
• 18 Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101: 1481-1483.
• 19 Bae JS, Rezaie AR. Activated protein C inhibits high mobility group box 1 signalling in endothelial cells. Blood 2011; 118: 3952-3959.
• 20 Lee W, Yoo H, Ku SK. et al. Anticoagulant activities of piperlonguminine in vitro and in vivo. BMB Rep 2013; 46: 484-489.
• 21 Yoo H, Ku SK, Lee W. et al. Antiplatelet, anticoagulant, and profibrinolytic activities of cudratricusxanthone A. Arch Pharm Res 2014; 37: 1069-1078.
• 22 Lee W, Ku SK, Lee YM. et al. Anti-septic effects of glyceollins in HMGB1-induced inflammatory responses in vitro and in vivo. Food Chem Toxicol 2014; 63: 1-8.
• 23 Wang H, Liao H, Ochani M. et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10: 1216-1221.
• 24 Bae JS, Lee W, Rezaie AR. Polyphosphate elicits pro-inflammatory responses that are counteracted by activated protein C in both cellular and animal models. J Thromb Haemost 2012; 10: 1145-1151.
• 25 Lee JD, Huh JE, Jeon G. et al. Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. Int Immunopharmacol 2009; 09: 268-276.
• 26 Sukhumavasi W, Egan CE, Denkers EY. Mouse neutrophils require JNK2 MAPK for Toxoplasma gondii-induced IL-12p40 and CCL2/MCP-1 release. J Immunol 2007; 179: 3570-3577.
• 27 Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6–8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol 1993; 151: 2399-2408.
• 28 Wolfson RK, Chiang ET, Garcia JG. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc Res 2011; 81: 189-197.
• 29 Sorci G, Riuzzi F, Giambanco I. et al. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta 2013; 1833: 101-109.
• 30 Lee JH, Katakai T, Hara T. et al. Roles of p-ERM and Rho-ROCK signalling in lymphocyte polarity and uropod formation. J Cell Biol 2004; 167: 327-337.
• 31 Hebert M, Potin S, Sebbagh M. et al. Rho-ROCK-dependent ezrin-radixinmoesin phosphorylation regulates Fas-mediated apoptosis in Jurkat cells. J Immunol 2008; 181: 5963-5973.
• 32 Ivetic A, Ridley AJ. Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology 2004; 112: 165-176.
• 33 Bardwell AJ, Frankson E, Bardwell L. Selectivity of docking sites in MAPK kinases. J Biol Chem 2009; 284: 13165-13173.
• 34 Qin YH, Dai SM, Tang GS. et al. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J Immunol 2009; 183: 6244-6250.
• 35 Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 05: 331-342.
• 36 Sun C, Liang C, Ren Y. et al. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 2009; 104: 42-49.
• 37 Lee W, Ku S, Yoo H. et al. Andrographolide inhibits HMGB1-induced inflammatory responses in human umbilical vein endothelial cells and in murine poly-microbial sepsis. Acta Physiol 2014; 211: 176-187.
• 38 Zhou W, Oh J, Wonhwa L. et al. The first cyclomegastigmane rhododendroside A from Rhododendron brachycarpum alleviates HMGB1-induced sepsis. Biochim Biophys Acta 2014; 1840: 2042-2049.
• 39 Yoo H, Ku SK, Han MS. et al. Anti-septic Effects of Fisetin In Vitro and In Vivo. Inflammation 2014; 37: 1560-1574.
• 40 Bogatcheva NV, Adyshev D, Mambetsariev B. et al. Involvement of micro-tubules, p38, and Rho kinases pathway in 2-methoxyestradiol-induced lung vascular barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2007; 292: L487-499.
• 41 Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med 1998; 26: 2078-2086.
• 42 Ventetuolo CE, Levy MM. Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med 2008; 29: 591-603 vii.
• 43 Tohme ZN, Amar S, Van Dyke TE. Moesin functions as a lipopolysaccharide receptor on human monocytes. Infect Immun 1999; 67: 3215-3220.
• 44 Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005; 04: 854-865.
• 45 Abraham E, Wunderink R, Silverman H. et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. J Am Med Assoc 1995; 273: 934-941.
• 46 Abraham E, Anzueto A, Gutierrez G. et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351: 929-933.
• 47 Okusawa S, Gelfand JA, Ikejima T. et al. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162-1172.
• 48 Fisher Jr. CJ, Dhainaut JF, Opal SM. et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. J Am Med Assoc 1994; 271: 1836-1843.
• 49 Opal SM, Fisher Jr. CJ, Dhainaut JF. et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-1124.
• 50 Vincent JL. Search for effective immunomodulating strategies against sepsis. Lancet 1998; 351: 922-923.
• 51 Dellinger RP. Severe sepsis trials: why have they failed?. Minerva Anestesiol 1999; 65: 340-345.